Income Statement ICAD
Stocks
ICAD
US44934S2068
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.870 USD | +3.75% |
|
-.--% | - |
| 25-07-20 | ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P TMI Index | CI |
| 25-07-17 | ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Value Benchmark Index | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 29.7M | 33.64M | 27.94M | 17.32M | 19.61M | |||||
Total Revenues | 29.7M | 33.64M | 27.94M | 17.32M | 19.61M | |||||
Cost of Goods Sold, Total | 7.96M | 9.08M | 7.84M | 2.45M | 2.59M | |||||
Gross Profit | 21.73M | 24.56M | 20.11M | 14.87M | 17.02M | |||||
Selling General & Admin Expenses, Total | 22.43M | 25.54M | 24.92M | 17.06M | 15.87M | |||||
R&D Expenses | 8.11M | 9.19M | 8.59M | 5.16M | 6.61M | |||||
Depreciation & Amortization - (IS) | 578K | 557K | 521K | 335K | 623K | |||||
Other Operating Expenses, Total | 31.12M | 35.29M | 34.04M | 22.56M | 23.1M | |||||
Operating Income | -9.39M | -10.73M | -13.93M | -7.69M | -6.08M | |||||
Interest Expense, Total | -476K | -141K | -10K | -16K | -12K | |||||
Interest And Investment Income | 97K | 15K | 213K | 729K | 811K | |||||
Net Interest Expenses | -379K | -126K | 203K | 713K | 799K | |||||
Other Non Operating Income (Expenses) | - | - | -45K | -14K | -49K | |||||
EBT, Excl. Unusual Items | -9.77M | -10.86M | -13.77M | -6.99M | -5.33M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | - | - | - | - | -184K | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | -7.8M | -386K | - | - | - | |||||
EBT, Incl. Unusual Items | -17.57M | -11.24M | -13.77M | -6.99M | -5.52M | |||||
Income Tax Expense | 38K | 1K | -116K | 20K | 98K | |||||
Earnings From Continuing Operations | -17.61M | -11.24M | -13.66M | -7.01M | -5.62M | |||||
Earnings Of Discontinued Operations | - | - | - | 2.16M | - | |||||
Net Income to Company | -17.61M | -11.24M | -13.66M | -4.85M | -5.62M | |||||
Net Income - (IS) | -17.61M | -11.24M | -13.66M | -4.85M | -5.62M | |||||
Net Income to Common Incl Extra Items | -17.61M | -11.24M | -13.66M | -4.85M | -5.62M | |||||
Net Income to Common Excl. Extra Items | -17.61M | -11.24M | -13.66M | -7.01M | -5.62M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.8 | -0.45 | -0.54 | -0.19 | -0.21 | |||||
Basic EPS - Continuing Operations | -0.8 | -0.45 | -0.54 | -0.27 | -0.21 | |||||
Basic Weighted Average Shares Outstanding | 22.14M | 24.78M | 25.2M | 25.61M | 26.35M | |||||
Net EPS - Diluted | -0.8 | -0.45 | -0.54 | -0.19 | -0.21 | |||||
Diluted EPS - Continuing Operations | -0.8 | -0.45 | -0.54 | -0.27 | -0.21 | |||||
Diluted Weighted Average Shares Outstanding | 22.14M | 24.78M | 25.2M | 25.61M | 26.35M | |||||
Normalized Basic EPS | -0.28 | -0.27 | -0.34 | -0.17 | -0.13 | |||||
Normalized Diluted EPS | -0.28 | -0.27 | -0.34 | -0.17 | -0.13 | |||||
Supplemental Items | ||||||||||
EBITDA | -8.81M | -10.18M | -13.41M | -7.28M | -5.46M | |||||
EBITA | -9.08M | -10.5M | -13.72M | -7.52M | -6.04M | |||||
EBIT | -9.39M | -10.73M | -13.93M | -7.69M | -6.08M | |||||
EBITDAR | -7.76M | -9.13M | -12.27M | -6.98M | -5.21M | |||||
Total Revenues (As Reported) | 29.7M | 33.64M | 27.94M | 17.32M | 19.61M | |||||
Effective Tax Rate - (Ratio) | -0.22 | -0.01 | 0.84 | -0.29 | -1.78 | |||||
Current Domestic Taxes | 37K | - | - | - | - | |||||
Total Current Taxes | 37K | - | - | - | - | |||||
Deferred Domestic Taxes | 1K | 1K | - | 1K | 1K | |||||
Deferred Foreign Taxes | - | - | -116K | 19K | 97K | |||||
Total Deferred Taxes | 1K | 1K | -116K | 20K | 98K | |||||
Normalized Net Income | -6.1M | -6.79M | -8.61M | -4.37M | -3.33M | |||||
Interest on Long-Term Debt | 476K | 141K | 10K | 16K | 12K | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 211K | 689K | 659K | 200K | 477K | |||||
Selling and Marketing Expenses | 13.31M | 15.14M | 13.69M | 7.74M | 8.42M | |||||
General and Administrative Expenses | 9.12M | 10.41M | 11.23M | 9.32M | 7.44M | |||||
Research And Development Expense From Footnotes | 8.11M | 9.19M | 8.59M | 5.16M | 6.61M | |||||
Net Rental Expense, Total | 1.05M | 1.05M | 1.14M | 298K | 254K | |||||
Imputed Operating Lease Interest Expense | 256K | 238K | 40.03K | 67.33K | 59.26K | |||||
Imputed Operating Lease Depreciation | 793K | 810K | 1.1M | 231K | 195K | |||||
Stock-Based Comp., COGS (Total) | 30K | 15K | 3K | 2K | 1K | |||||
Stock-Based Comp., R&D Exp. (Total) | 376K | 356K | 220K | 222K | 134K | |||||
Stock-Based Comp., S&M Exp. (Total) | 657K | 785K | 518K | 308K | 158K | |||||
Stock-Based Comp., G&A Exp. (Total) | 1.78M | 1.63M | 945K | 784K | 590K | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 2.84M | 2.78M | 1.69M | 1.32M | 883K |
- Stock Market
- Stocks
- ICAD Stock
- Financials ICAD
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















